Erika Jones - Black Diamond Corporate Finance
| BDTX Stock | USD 2.57 0.10 4.05% |
Executive
Erika Jones is Corporate Finance of Black Diamond Therapeutics
| Age | 39 |
| Address | One Main Street, Cambridge, MA, United States, 02142 |
| Phone | 617 252 0848 |
| Web | https://www.blackdiamondtherapeutics.com |
Erika Jones Latest Insider Activity
Tracking and analyzing the buying and selling activities of Erika Jones against Black Diamond stock is an integral part of due diligence when investing in Black Diamond. Erika Jones insider activity provides valuable insight into whether Black Diamond is net buyers or sellers over its current business cycle. Note, Black Diamond insiders must abide by specific rules, including filing SEC forms every time they buy or sell Black Diamond'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Erika Jones over two months ago Acquisition by Erika Jones of 100000 shares of Black Diamond at 4.86 subject to Rule 16b-3 |
Black Diamond Management Efficiency
The company has return on total asset (ROA) of (0.3278) % which means that it has lost $0.3278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6309) %, meaning that it created substantial loss on money invested by shareholders. Black Diamond's management efficiency ratios could be used to measure how well Black Diamond manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. At this time, Black Diamond's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 100.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Huw Nash | Stoke Therapeutics | 57 | |
| Dennis Williams | Adaptimmune Therapeutics Plc | N/A | |
| Karl Whitney | Passage Bio | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| Stuart Henderson | Passage Bio | N/A | |
| Virginia MBA | Alector | N/A | |
| Kristina MPH | Alector | N/A | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Gary MD | Alector | 62 | |
| Katie Hogan | Alector | N/A | |
| Erin Graves | Revolution Medicines | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Norah Conway | Alector | N/A | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Gregory Fuest | Passage Bio | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| JD Esq | Passage Bio | 60 | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| MS MBA | Alector | 49 | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.33 |
Black Diamond Therap Leadership Team
Elected by the shareholders, the Black Diamond's board of directors comprises two types of representatives: Black Diamond inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Black. The board's role is to monitor Black Diamond's management team and ensure that shareholders' interests are well served. Black Diamond's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Black Diamond's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melanie Morrison, Sr Operations | ||
| Fang PharmD, Principal CFO | ||
| Christopher Roberts, Advisor | ||
| Elizabeth Montgomery, Chief Officer | ||
| TaiAn Lin, VP Biology | ||
| JD Esq, COO Counsel | ||
| Elizabeth Buck, CoFounder Officer | ||
| Sergey MD, Chief Officer | ||
| David Epstein, President, CoFounder | ||
| Erika Jones, Corporate Finance |
Black Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Black Diamond a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 55.74 M | ||||
| Shares Outstanding | 56.59 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 98.99 % | ||||
| Number Of Shares Shorted | 5.94 M | ||||
| Price To Book | 1.49 X | ||||
| EBITDA | (86.02 M) | ||||
| Net Income | (82.44 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Black Stock Analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.